Белгија - Енглески - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aspen pharma trading ltd. - desogestrel 25 µg (blue tablet); ethinylestradiol 40 µg (blue tablet); desogestrel 125 µg (white tablet); ethinylestradiol 30 µg (white tablet) - tablet - 0,040 mg - 0,025 mg - desogestrel 25 µg; ethinylestradiol 40 µg; desogestrel 125 µg; ethinylestradiol 30 µg - desogestrel and ethinylestradiol

Малта - Енглески - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - desogestrel, ethinylestradiol - film-coated tablet - desogestrel 150 µg ethinylestradiol 30 µg - sex hormones and modulators of the genital system

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - enskyce tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with enskyce, 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. emergency contraceptive pills: treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%.4 lactation amenorrhea method: lam is a highly effective, temporary method of contraception.5 source: trussell j. contraceptive efficacy. in hatcher ra, trussell j, stewart f, cates w, stewart gk, kowel d, guest f, contraceptive technology: seventeenth revised edition. new york, ny; irvington publishers, 1998. 1 among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. 2 among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 3 among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 4 the treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. the fda has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: ovral® (1 dose is 2 white pills), alesse® (1 dose is 5 pink pills), nordette® or levlen® (1 dose is 4 yellow pills). 5 however, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency of duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age. 6 the percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. among such populations, about 89% become pregnant within one year. this estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 7 foams, creams, gels, vaginal suppositories, and vaginal film. 8 cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. 9 with spermicidal cream or jelly. 1 0 without spermicides. enskyce has not been studied for and is not indicated for use in emergency contraception. enskyce is contraindicated in females who are known to have or develop the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - known thrombophilic conditions - cerebral vascular or coronary artery disease (current or history) - valvular heart disease with complications - persistent blood pressure values of ≥160 mm hg systolic or ≥100 mg hg diastolic102 - diabetes with vascular involvement - headaches with focal neurological symptoms - major surgery with prolonged immobilization - current diagnosis of, or history of, breast cancer, which may be hormonesensitive - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - undiagnosed abnormal genital bleeding - cholestatic jaundice of pregnancy or jaundice with prior pill use - acute or chronic hepatocellular disease with abnormal liver function - hepatic adenomas or carcinomas - known or suspected pregnancy - hypersensitivity to any component of this product - are receiving hepatitis c drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alt elevations (see section 5 in warnings, risk of liver enzyme elevations with concomitant hepatitis c treatment ).

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - desogestrel; ethinylestradiol - oral tablet - 150microgram ; 30microgram

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

lupin limited - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - ethinyl estradiol 0.03 mg - enskyce tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with enskyce, 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. emergency contraceptive pills: treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%.4 lactation amenorrhea method: lam is a high

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - ethinyl estradiol 0.03 mg - enskyce tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with enskyce, 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. emergency contraceptive pills: treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%.4 lactation amenorrhea method: lam is a high

Зимбабве - Енглески - Medicines Control Authority

lupin limited - desogestrel; ethinyl estradiol - tablet; oral - 0.15mg/0.03mg

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

dr. reddy’s laboratories inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - azurette (desogestrel and ethinyl estradiol tablets, usp and ethinyl estradiol tablets, usp) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and coosistent use of these methods can result in lower failure rates. adapted from hatcher et al., 1998, ref#1. 1 among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 2 among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 3 among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. 4 the percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. among such populations, about 89% become pregnant within one year. this estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 5 foams, creams, gels, vaginal suppositories, and vaginal film. 6 cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. 7 with spermicidal cream or jelly. 8 without spermicides. oral contraceptives should not be used in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease - current diagnosis of, or history of, breast cancer, which may be hormone-sensitive - undiagnosed abnormal genital bleeding - cholestatic jaundice of pregnancy or jaundice with prior pill use - hepatic adenomas or carcinomas - are receiving hepatitis c drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alt elevations (see warnings, risk of liver enzyme elevations with concomitant hepatitis c treatment )

Малта - Енглески - Medicines Authority

merck sharp & dohme limited - desogestrel; ethinylestradiol - tablet - desogestrel 150 µg; ethinylestradiol 20 µg - sex hormones and modulators of the genital system

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - desogestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; potato starch - oral contraception.